ArticleClinical Medicine Insights. Oncology2024

Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China.

Meiling Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.